Posts by neonadmin
Advocacy in Action
Solving Kids’ Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC’s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma.
Read MorePrecision Medicine Advances for Children With Neuroblastoma
Solving Kids’ Cancer (SKC) together with Wade’s Army announce their joint financial support of this Phase 1 clinical trial to test the safety and efficacy of various investigational drugs that will leverage precision medicine for children with neuroblastoma. This Next Generation Personalized Neuroblastoma Therapy – also known as NEPENTHE (Greek for “medicine for sorrow”) – is the first precision medicine trial for children that will robustly analyze the genomics of their cancer and use combinations of investigational drugs to target specific mutations in their tumors.
Read MoreChildren with High Grade Brain Tumors will be able to Receive Cutting-edge Oncolytic Virus Therapy
The Andrew McDonough B+ Foundation (The B+ Foundation) and Solving Kids’ Cancer (SKC) presented a check for $208,500 to Dr. Matthias Gromeier and Dr. Eric Thompson at the Preston Robert Tisch Brain Tumor Center at Duke, to co-fund an exciting new immunotherapy trial for children with deadly brain tumors.
Read MoreThe Launch of an International Immunotherapy Trial for Children with Brain Tumors
A Kids’ Brain Tumor Cure Foundation, Solving Kids’ Cancer, and the Ty Louis Campbell (TLC) Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Read MoreSKC Formally Appeals NICE Decision
The National Institute for Health and Care Excellence (NICE) heard an appeal led by Solving Kids’ Cancer (SKC) against its recent decision to deny children in the UK treatment that is proven to significantly increase the chance of survival for children diagnosed with an aggressive childhood cancer, neuroblastoma.
Read MoreAccess to Cures Should Have No Borders
The British healthcare system has rejected an FDA/EMA-approved treatment proven to increase survival rates for children with cancer. NICE (National Institute for Health and Care Excellence) has rejected access to the drug across the UK, stating cost as the reason. However, when analyzing the real expense on taxpayers, the cost amounts to less than 3 pence per person, per year, in order to give these children access to the life-saving antibody.
Read MoreAccelerating Research For Pediatric Brain Tumors
Meet Dr. Mark Souweidane from Weill Cornell Medical Center and listen in as we interview him and two childhood cancer families about his clinical trial that Solving Kids’ Cancer funded for children with brain tumors.
Read MoreChildren’s Cancer is Unprofitable and Ignored – An SKC Featured Article
John London, co-founder of SKC, wanted to scream in frustration. After three years of treatment, doctors suggested that him and his wife took his daughter, Penelope, home to enjoy their remaining time together. Instead, John scanned hundreds of research abstracts seeking new treatments.
Read MoreUnderstanding the Landscape, Strengthening the Science, Curing and Caring for the Child
Solving Kids’ Cancer’s approach is to understand the research landscape, strengthen the science, cure, and care for the child. The GD2 T Cell Therapy trial at Texas Children’s Hospital is helping children with neuroblastoma like Kyra Kardong – listen to her story.
Read MoreThe Promise of Immunotherapy
Immunotherapy is changing the paradigm for children with cancer. Solving Kids’ Cancer has teamed up with the same researchers who helped save Emily Whitehead’s life to bring a new treatment option for children with neuroblastoma. Meet one family that was on a Solving Kids’ Cancer clinical trial at the Children’s Hospital of Philadelphia
Read More